Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.

NCT00634621 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT00634621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00634621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.
Lead sponsor
GE Healthcare
Phase
Observational
Overall status
Completed
Start date
February 29, 2008
Completion date
September 30, 2010
Enrollment
283 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer